MedPath

Curcumin

Generic Name
Curcumin
Drug Type
Small Molecule
Chemical Formula
C21H20O6
CAS Number
458-37-7
Unique Ingredient Identifier
IT942ZTH98

Overview

Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell Lung Cancer (NSCLC). Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin . Curcumin is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment (MCI) .

Background

Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell Lung Cancer (NSCLC). Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin . Curcumin is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment (MCI) .

Indication

No approved therapeutic indications.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/03/20
Phase 4
Not yet recruiting
Erzincan Military Hospital
2025/01/06
Phase 3
Not yet recruiting
Services Institute of Medical Sciences, Pakistan
2024/09/20
Phase 3
Completed
Shaymaa Hussein Rafat Kotb
2024/06/24
Phase 2
Not yet recruiting
2024/04/24
Phase 3
Recruiting
2024/04/11
Phase 1
ENROLLING_BY_INVITATION
Brent DeGeorge
2024/04/02
Phase 2
Active, not recruiting
2024/02/28
Phase 2
Completed
2023/09/21
Phase 1
Completed
2023/08/08
Not Applicable
Completed

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
Meriva Curcumin
276665
Medicine
A
6/16/2016
USANA HealthPak
350153
Medicine
A
11/30/2020
Pain Relief Cream
372433
Medicine
A
8/9/2021
METAGENICS INFLAGESIC
387454
Medicine
A
4/26/2022
JoinTQ
384091
Medicine
A
2/16/2022
My Alai™ Multisystem Support
408964
Medicine
A
5/15/2023
Swisse Ultiboost Curcumin
273666
Medicine
A
3/31/2016
Cellgevity
294661
Max Health & Living Australia Pty Ltd
Medicine
A
10/5/2017
BounceBack
427921
Mannatech Australia Pty Ltd
Medicine
A
11/15/2023
Caruso's Turmeric
286551
Medicine
A
3/9/2017
© Copyright 2025. All Rights Reserved by MedPath